Providence Capital Advisors, LLC Gilead Sciences, Inc. Transaction History

Providence Capital Advisors, LLC

$487 Million
Q3 2024

A detailed history of Providence Capital Advisors, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Providence Capital Advisors, LLC holds 430 shares of GILD stock, worth $38,012. This represents 0.01% of its overall portfolio holdings.

Number of Shares

430

Previous 429 0.23%

Holding current value

$38,012

Previous $29,000 24.14%

% of portfolio

0.01%

Previous 0.01%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$66.59 - $83.99 $66 - $83	1 Added 0.23%	430 $36,000
Q2 2024 Aug 14, 2024	BUY	$63.15 - $72.88 $63 - $72	1 Added 0.23%	429 $29,000
Q1 2024 May 13, 2024	BUY	$71.58 - $87.29 $143 - $174	2 Added 0.47%	428 $31,000
Q3 2023 Nov 13, 2023	BUY	$73.94 - $80.67 $147 - $161	2 Added 0.47%	426 $31,000
Q2 2023 Aug 10, 2023	BUY	$76.01 - $86.7 $16,342 - $18,640	215 Added 102.87%	424 $32,000
Q1 2023 May 17, 2023	SELL	$77.31 - $88.08 $9.66 Million - $11 Million	-124,961 Reduced 87.77%	17,413 $1.44 Million
Q1 2023 May 17, 2023	SELL	$77.31 - $88.08 $1.33 Million - $1.52 Million	-17,204 Reduced 98.8%	209 $17,000
Q1 2023 May 10, 2023	BUY	$77.31 - $88.08 $11 Million - $12.5 Million	142,165 Added 68021.53%	142,374 $11.8 Million
Q4 2022 Feb 07, 2023	BUY	$62.32 - $89.47 $62 - $89	1 Added 0.48%	209 $17,000
Q3 2022 Nov 09, 2022	SELL	$59.54 - $68.01 $535 - $612	-9 Reduced 4.15%	208 $13,000
Q2 2022 Aug 09, 2022	BUY	$57.72 - $65.01 $5,887 - $6,631	102 Added 88.7%	217 $13,000
Q1 2022 May 12, 2022	BUY	$57.92 - $72.58 $57 - $72	1 Added 0.88%	115 $6,000
Q4 2021 Feb 11, 2022	SELL	$64.88 - $73.64 $64 - $73	-1 Reduced 0.87%	114 $8,000
Q3 2021 Nov 09, 2021	SELL	$67.69 - $73.03 $4.28 Million - $4.62 Million	-63,199 Reduced 99.82%	115 $8,000
Q2 2021 Aug 09, 2021	BUY	$63.47 - $69.35 $164,450 - $179,685	2,591 Added 4.27%	63,314 $4.36 Million
Q1 2021 May 13, 2021	BUY	$60.0 - $68.46 $127,260 - $145,203	2,121 Added 3.62%	60,723 $3.93 Million
Q4 2020 Feb 11, 2021	BUY	$56.65 - $64.55 $662,805 - $755,235	11,700 Added 24.95%	58,602 $3.41 Million
Q3 2020 Nov 13, 2020	BUY	$62.1 - $78.08 $602,370 - $757,376	9,700 Added 26.07%	46,902 $2.96 Million
Q2 2020 Aug 04, 2020	SELL	$72.34 - $84.0 $679,851 - $789,432	-9,398 Reduced 20.17%	37,202 $2.86 Million
Q1 2020 May 12, 2020	BUY	$62.63 - $80.22 $118,997 - $152,418	1,900 Added 4.25%	46,600 $3.48 Million
Q4 2019 Feb 13, 2020	BUY	$61.62 - $67.78 $2.75 Million - $3.03 Million	44,700 New	44,700 $2.91 Million
Q3 2019 Nov 13, 2019	SELL	$62.51 - $69.0 $375 - $414	-6 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$61.87 - $69.38 $371 - $416	6 New	6 $0
Q4 2018 Feb 01, 2019	SELL	$60.54 - $79.0 $2,421 - $3,160	-40 Closed	0 $0
Q2 2018 Aug 08, 2018	SELL	$64.88 - $75.68 $4,736 - $5,524	-73 Reduced 64.6%	40 $3,000
Q4 2017 Feb 12, 2018	BUY	$71.15 - $83.52 $8,039 - $9,437	113	113 $8,000

Others Institutions Holding GILD

# of Institutions

1,926

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $111B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Providence Capital Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Providence Capital Advisors, LLC with notifications on news.

Account

Providence Capital Advisors, LLC Gilead Sciences, Inc. Transaction History